Venkatraman Radhakrishnan/stjude.org
Sep 26, 2023, 19:20
Venkatraman Radhakrishnan: Reduction in chemo dose intensity by 25% and adding Rituximab improves survival in pediatric high-grade B Non-Hodgkins Lymphoma in resource-limited settings.
Venkatraman Radhakrishnan, , recently shared the following insight on X/Twitter:
“Reduction in chemo dose intensity by 25% and adding Rituximab improves survival in pediatric high-grade B Non-Hodgkins Lymphoma in resource-limited settings.
Outcomes are comparable to high-income countries. A 25% improvement in survival compared to the past.
-Malnutrition and MDR Gram-negative bacteria associated with increased mortality in pediatric B NHL in LMICs.
-A less dose-intense protocol reduces toxicity and treatment-related mortality and allows for giving chemo on time thereby reducing relapses.
-Rituximab compensates for the reduction in dose intensity.”
For the article click here.
Source: Vnkatraman Radhakrishnan/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 23, 2024, 16:19
Dec 23, 2024, 15:26
Dec 23, 2024, 15:13
Dec 23, 2024, 15:10